Patents by Inventor Jerry Ting

Jerry Ting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250238433
    Abstract: Systems, apparatuses, and methods for enabling a user to formulate and execute a query against a corpus of documents and do so in a computationally efficient and scalable manner
    Type: Application
    Filed: January 21, 2025
    Publication date: July 24, 2025
    Inventors: Jacob Sussman, Amine Anoun, Jerry Ting, Riley Hawkins, Xinying Yu, Isabella Fu, Andrew Johnson, David May
  • Publication number: 20240160838
    Abstract: A method for enabling a user to select and interact with text, lines, or paragraphs of a document, in the case where the document is available as a PDF or image. Embodiments enable the representation of a document to go beyond simple extraction of text, including organizing the text into logical groups of benefit to a user, such as paragraph, header, footer, or table (as examples), and labelling them as such. This facilitates subsequent processing, including application of machine learning (ML) algorithms to leverage this explicit information.
    Type: Application
    Filed: November 13, 2023
    Publication date: May 16, 2024
    Inventors: Amine Anoun, Andrew Johnson, Jacob Sussman, Jerry Ting, Riley Hawkins, Derek Peterson
  • Publication number: 20240067746
    Abstract: Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.
    Type: Application
    Filed: February 28, 2023
    Publication date: February 29, 2024
    Inventors: Tong-Hsuan CHANG, Mei-Chun YANG, Liahng-Yirn LIU, Jerry TING, Shu-Yen CHANG, Yen-Ying CHEN, Yu-Yu LIN, Shu-Lun TANG
  • Patent number: 11643471
    Abstract: Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: May 9, 2023
    Assignee: GlycoNex Inc.
    Inventors: Tong-Hsuan Chang, Mei-Chun Yang, Liahng-Yirn Liu, Jerry Ting, Shu-Yen Chang, Yen-Ying Chen, Yu-Yu Lin, Shu-Lun Tang
  • Publication number: 20220403042
    Abstract: Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.
    Type: Application
    Filed: July 26, 2022
    Publication date: December 22, 2022
    Inventors: Tong-Hsuan CHANG, Mei-Chun YANG, Liahng-Yirn LIU, Jerry TING, Shu-Yen CHANG, Yen-Ying CHEN, Yu-Yu LIN, Shu-Lun TANG
  • Patent number: 11440967
    Abstract: Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 13, 2022
    Assignee: GlycoNex Inc.
    Inventors: Tong-Hsuan Chang, Mei-Chun Yang, Liahng-Yim Liu, Jerry Ting, Shu-Yen Chang, Yen-Ying Chen, Yu-Yu Lin, Shu-Lun Tang
  • Publication number: 20190367632
    Abstract: Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 5, 2019
    Inventors: Tong-Hsuan CHANG, Mei-Chun YANG, Liahng-Yirn LIU, Jerry TING, Shu-Yen CHANG, Yen-Ying CHEN, Yu-Yu LIN, Shu-Lun TANG
  • Patent number: 8703129
    Abstract: Disclosed herein are antibodies or antigen-binding portions thereof directed against extended Type I chain antigens, in particular extended Type I chain glycosphingolipids, and the uses of the antibodies or antigen-binding portions thereof in the diagnosis, amelioration, treatment or prevention of diseases or disorders in mammals, including humans, resulting from or associated with the improper activity/metabolism or the presence of extended Type I chain antigens, in particular extended Type I chain glycosphingolipids.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: April 22, 2014
    Assignee: GlycoNex, Inc.
    Inventors: Tong-Hsuan Chang, Jerry Ting, Mei-Chin Yang, Liahng-Yirn Liu, Shu-Yen Chang, Chia-Hao Chang
  • Publication number: 20120184717
    Abstract: Disclosed herein are antibodies or antigen-binding portions thereof directed against extended Type I chain antigens, in particular extended Type I chain glycosphingolipids, and the uses of the antibodies or antigen-binding portions thereof in the diagnosis, amelioration, treatment or prevention of diseases or disorders in mammals, including humans, resulting from or associated with the improper activity/metabolism or the presence of extended Type I chain antigens, in particular extended Type I chain glycosphingolipids.
    Type: Application
    Filed: March 29, 2012
    Publication date: July 19, 2012
    Applicant: Glyconex Inc.
    Inventors: Tong-Hsuan Chang, Jerry Ting, Mei-Chun Yang, Liahng-Yirn Liu, Shu-Yen Chang, Chia-Hao Chang
  • Patent number: 8163497
    Abstract: Human antibodies and antigen-binding portions of those antibodies that specifically bind extended Type I chain glycosphingolipids are provided.
    Type: Grant
    Filed: September 7, 2008
    Date of Patent: April 24, 2012
    Assignee: Glyconex Inc.
    Inventors: Tong-Hsuan Chang, Jerry Ting, Tsai-Hsia Hong, Mei-Chun Yang, Liahng-Yirn Liu, Shu-Yen Chang, Ying-Jin Chen, Jaw-Yuan Wen, Kazuko Handa, Sen-itiroh Hakomori
  • Publication number: 20110142844
    Abstract: Human antibodies and antigen-binding portions of those antibodies that specifically bind extended Type I chain glycosphingolipids are provided.
    Type: Application
    Filed: September 7, 2008
    Publication date: June 16, 2011
    Applicant: GLYCONEX INC.
    Inventors: Tong-Hsuan Chang, Jerry Ting, Tsai-Hsia Hong, Mei-Chun Yang, Liahng-Yirn Liu, Shu-Yen Chang, Ying-Jin Chen, Jaw-Yuan Wen, Kazuko Handa, Sen-itiroh Hakomori
  • Patent number: 6248554
    Abstract: The present invention relates to an isolated BMP receptor kinase protein or soluble fragment thereof, a DNA sequence coding for said BMP receptor kinase protein or said soluble fragment thereof, a recombinant expression vector comprising said DNA sequence, a host cell comprising said recombinant expression vector, a method of expressing said BMP receptor kinase protein or soluble fragment thereof, a method for identifying compounds capable of binding to said BMP receptor kinase protein or soluble fragment thereof, a method for determining the amount of such compounds in a sample, and antibodies to said BMP receptor kinase protein.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: June 19, 2001
    Assignee: The Procter & Gamble Company
    Inventors: Jonathan Shaun Cook, Paul Elliott Correa, Jan Susan Rosenbaum, Jerry Ting